Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database - Quiz - MDSpire

Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database

  • By

  • Ruming Liu

  • Yaoyu Xiang

  • Xidan Hu

  • Min Zhang

  • Lujie Wang

  • Tao Liu

  • Xi Wang

  • Bin Qian

  • June 18, 2026

  • 0 min

Share

Original Source(s)

Ipilimumab and nivolumab for cancer treatment: a pharmacovigilance study based on the FDA adverse event reporting system database

  • by Ruming Liu, Yaoyu Xiang, Xidan Hu, Min Zhang, Lujie Wang, Tao Liu, Xi Wang, Bin Qian

  • June 18, 2026

Related Content

Correction: MAPRE2 is associated with macrophage-enriched innate immune dysregulation and malignant phenotypes in hepatocellular carcinoma

Endocrine therapy and thyroid function in early luminal breast cancer: a controlled longitudinal retrospective analysis

CT-based radiomics improves survival prediction in colorectal liver metastases: beyond clinical scores